Embed Size (px)
Citation preview
PATH Dan Laster | Chief Opera1ng Officer and General Counsel Developing Products to Improve Global Health
October 27 2016
LAND AREA
Page 2 www.worldmapper.org
POPULATION
Page 3 www.worldmapper.org
RESEARCH AND DEVELOPMENT SPENDING
Page 4 www.worldmapper.org
PUBLIC HEALTH SPENDING
Page 5 www.worldmapper.org
VACCINE PREVENTABLE DEATHS
Page 6 www.worldmapper.org
SOLUT ION: DR IVE TRANSFORMATIVE INNOVAT ION IN GLOBAL HEALTH
PATH/Umit Kartoglu
Work in more than 70 countries 150 million people reached each year (average)
Our global impact
6.3 million people reached with rice for1fied with cri1cal micronutrients
6.2 million lives saved with PATH-‐pioneered approaches to malaria control
6 billion vaccine vial monitors ensuring that vaccines are potent when given
AcceleraHng global health innovaHons
ExperHse and programs across five plaNorms
Working across the value chain, focusing on the middle
Research / Design
Develop / Validate
Approve / Recommend
Introduce / Op1mize
Scale up / Apply
Vaccines Drugs Diagnos1cs Devices System & Service Innova1ons
PATH’S ROLE : CATALYZ ING CROSS -‐SECTOR COLLABORAT ION FOR IMPACT…
… b y b u i l d i n g e v i d e n c e a n d b r i d g i n g t h e v a l u e c h a i n o f i n n o v a H o n
C i v i l S o c i e t y
P u b l i c P r i v a t e
IMPACT
Scale-‐up Develop/ Validate IntroducHon Research/
Design Regulatory/
Policy
10
PotenHal returns
Developm
ent risk
Private sector
Developing world risk/return
PARTNERING UPSTREAM: PRODUCT DEVELOPMENT PARTNERSHIPS (PDP)
Develop/ Validate IntroducHon Research/
Design Regulatory/
Policy Scale up
11
• Mi1gate risk • Share costs
PotenHal returns
Developm
ent risk
Private sector
Developing world risk/return
PARTNERING UPSTREAM: PRODUCT DEVELOPMENT PARTNERSHIPS
PDP
Develop/ Validate IntroducHon Research/
Design Regulatory/
Policy Scale up
12
MUTUALLY BENEF IC IAL , COLLABORATIVE PRODUCT DEVELOPMENT PARTNERSHIPS
WHAT PATH BRINGS • Exper1se in developing country health systems
• Presence in low-‐income countries
• Ability to strengthen clinical trial capacity
• Financial support • Technical exper1se • Strategic rela1onships • Intellectual property
WHAT PARTNERS BRING • Exper1se in product development
• Scien1fic and technical capacity
• Intellectual property • Manufacturing facili1es & equipment
• Large-‐scale distribu1on systems
• Market-‐based approach
Mutual ben
efit
Develop/ Validate IntroducHon Research/
Design Regulatory/
Policy Scale up
13
DRIVERS OF PDP PARTNERSHIP DIVERSITY
State of Science or Technology
Intellectual Property
Time to Market
Clarity of Market
Distribu1on System Readiness
Partnership Complexity
Less certain More certain
Develop/ Validate IntroducHon Research/
Design Regulatory/
Policy Scale up
14
CRITICAL TERMS FOR GLOBAL ACCESS
Supply
Develop/ Validate IntroducHon Research/
Design Regulatory/
Policy Scale up
15
CASE: MENINGITIS A VACCINE
State of Science or Technology
Intellectual Property
Time to Market
Clarity of Market
Distribu1on System Readiness
Partnership Complexity
Less certain More certain
Develop/ Validate IntroducHon Research/
Design Regulatory/
Policy Scale up
16
Partnering to eliminate meningi1s epidemics
220 million protected: zero cases of meningi1s A
Legend By 2020, the vaccine will prevent:
• 1 million cases • 150,000 deaths
• 250,000 cases of severe disability
MULTI-‐SECTOR PARTNERSHIPS ARE EVOLVING…
19
MULTI-‐SECTOR PARTNERSHIPS ARE EVOLVING…
QUESTIONS?
PATH/ Gabe Bienczycki
L INKS TO PATH RESOURCES
Public-‐Private Partnerships for Global Health: How PATH Advances Technologies Through Cross-‐Sector Collabora1on PATH's Guiding Principles for Private-‐Sector Collabora1on PATH's Framework for Product Introduc1on PATH’s Commercializa1on Toolkit for Small-‐ and Medium-‐Sized Enterprises: Execu1ve Summary Developing a Total Market Plan for Family Planning in Vietnam: An Innova1ve Public and Private Collabora1on to Enhance Equity and Sustainability
21
